Laura Prendergast

Stock Analyst at Stifel Nicolaus

(4.64)
# 877
Out of 5,010 analysts
84
Total ratings
50.7%
Success rate
31.6%
Average return

Stocks Rated by Laura Prendergast

Olema Pharmaceuticals
Sep 14, 2026
Reiterated: Buy
Price Target: $48 → $30
Current: $8.54
Upside: +251.29%
Revolution Medicines
Sep 13, 2026
Reiterated: Buy
Price Target: $230
Current: $204.48
Upside: +12.48%
BridgeBio Oncology Therapeutics
Sep 9, 2026
Reiterated: Buy
Price Target: $23 → $15
Current: $3.92
Upside: +282.65%
Erasca
Aug 17, 2026
Reiterated: Buy
Price Target: $30
Current: $14.21
Upside: +111.12%
Foghorn Therapeutics
Aug 17, 2026
Reiterated: Buy
Price Target: $12
Current: $3.52
Upside: +240.91%
Sutro Biopharma
Aug 17, 2026
Reiterated: Buy
Price Target: $48
Current: $16.10
Upside: +198.14%
Tango Therapeutics
Aug 17, 2026
Reiterated: Buy
Price Target: $40
Current: $24.42
Upside: +63.80%
Black Diamond Therapeutics
Aug 6, 2026
Reiterated: Buy
Price Target: $8
Current: $1.87
Upside: +327.81%
ORIC Pharmaceuticals
Aug 4, 2026
Reiterated: Buy
Price Target: $14
Current: $13.37
Upside: +4.71%
Cogent Biosciences
Jun 15, 2026
Reiterated: Buy
Price Target: $45
Current: $31.66
Upside: +42.14%
Reiterated: Buy
Price Target: $12
Current: $10.55
Upside: n/a
Reiterated: Buy
Price Target: $4
Current: $8.94
Upside: n/a
Upgraded: Buy
Price Target: $16
Current: $2.62
Upside: n/a